Company Overview and News

 
KLCI pares loss as foreign selling slows down

2018-07-23 theedgemarkets
KUALA LUMPUR (July 23): The FBM KLCI pared some of its losses at midday break today, despite weaker regional markets, as foreign selling of local equities remained measured for the fourth week running.
HLFBF 7172 UPBMF 1082 BATS 4162 7006 2089 7055 LIIHF KLKBY 5238 2445 4588 3867 5738 0026

 
KLCI falls 0.77% as Trump's tariffs on China take effect

2018-07-06 theedgemarkets
KUALA LUMPUR (July 6): The FBM KLCI fell 0.77% at midday break as regional markets slumped, as U.S. tariffs against China took effect this afternoon.
PBLOF UPBMF 4065 6399 5681 1295 2089 7055 7154 5255 7277 CIMDF KLKBY 5139 1023 2445 0900 8613 0026 6888 2216 AXXTF

 
KLCI down 0.37% as index-linked banks drag

2018-07-06 theedgemarkets
KUALA LUMPUR (July 6): The FBM KLCI fell 0.37% art mid-morning today, dragged by index-linked banking stocks against the backdrop of mixed regional markets.
MLYBY MLYNF UPBMF 4065 BATS 4162 2089 7055 7154 5255 CIMDF 1155 5139 1023 0900 0026 6888 5819 AXXTF

 
KLCI starts flat, tracks volatile regional peers

2018-07-06 theedgemarkets
KUALA LUMPUR (July 6): The FBM KLCI opened flat this morning, tracking nervy regional markets, ahead of the U.S. deadline to commence to trade tariffs against China.
MLYBY MLYNF UPBMF 2089 7055 7277 1155 KLKBY 2445 3883 5347 TNABY 2836 TNABF

 
KLCI pares gains in line with shaky regional markets

2018-07-04 theedgemarkets
KUALA LUMPUR (July 4): The FBM KLCI pared some of its gains at mid-morning today in line with the shaky regional markets, as mounting worries of an escalating U.S.-China trade spat kept global investors on tenterhooks.
7084 4065 BATS 4162 1163 7374 7055 0120 KLKBY 5139 2445 4863 3867 0037 0900 0026 MYTEF 3719

10
KLCI reverses gains, falls 0.63% as regional markets slip

2018-07-03 theedgemarkets
KUALA LUMPUR (July 3): The FBM KLCI reversed its earlier gains and fell 0.63% at mid-morning today, as Asian markets slipped.
4006 KLKBY 5139 2445 0900 6888 7036 5681 AXXTF 1163 ORHLF 7055

21
KLCI remains muted as blue chips drag

2018-06-28 theedgemarkets
KUALA LUMPUR (June 28): The FBM KLCI remained muted at mid-morning today, in tandem with the decline at most regional markets, dragged by index-linked blue chips.
PBLOF MLYBY MLYNF UPBMF 8621 BATS 4162 1295 2089 7055 9334 6033 1155 PNADF 5347 TNABY 2836 TNABF PNAGF

 
Trading ideas: Maybank, Zhulian, PLB Engineering, Keck Seng

2018-04-19 thestar.com.my
KUALA LUMPUR: Malayan Bank Bhd (Maybank), Zhulian Corp Bhd , PLB Engineering Bhd and Keck Seng (M) Bhd are among the stocks to watch on Thursday, according to JF Apex Research.
3476 7055

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...